ilS Speaker Series: Drug P&R Criteria in the UK and Spain

Barcelona, 7th of March.

ilS celebrated its first year launching its first ilS Speaker SeriesSM at their head quarters, in Barcelona.

The objective of the ilS Speaker SeriesSM was to generate debate and create knowledge. And the topic chosen for the event focused on a comparison between the P&R criteria used in the UK and Spain.

Dr. Pepi Hurtado, partner at ilS and expert in the UK Health System, explained to attendees the current changes in the National Health Service (NHS), and how decisions are taken in regards to the introduction of new drugs in the NHS. On the other side, Dr. Poveda, President of the Spanish Society of Hospital Pharmacy (SEFH), presented to the attendees the current P&R criterion in Spain, focusing on the need of a single and transparent P&R system for drugs should be implemented.

Attendees included representatives of the pharmaceutical industry and pharmacy hospital managers across the most relevant Spanish Hospitals. In addition Dr. Argimon, director of the Catalan Drug Evaluation Agency (AQuAS), together with Dr. Revilla, president of the Spanish Society of bio Companies (ASEBIO) attended the event.

For further information please have a look at:

To download the ilS Speaker Series presentation click here:


From left to right: Dr. Argimon (Director of AQuAS), Dr. Hurtado (partner at ilS, speaker at the even), Dr. Revilla (President of ASEBIO), Dr. Poveda (President of SEFH, speaker at the event), Miss Merhart (Life Sciences Advisor at UKTI, speaker at the event) and Dr. Escudero (partner at ilS, speaker at the event)


2018-06-21T10:25:19+00:00 abril 9th, 2014|ilS Speaker Series|